tiprankstipranks
Advertisement
Advertisement

HK:1672 Stock Latest News

Ascletis launches global Phase III obesity trial and advances oral triple agonist portfolio
Company AnnouncementsAscletis launches global Phase III obesity trial and advances oral triple agonist portfolio
7d ago
1672
Ascletis Pharma Schedules Board Meeting to Review 2026 Interim Results and Dividend
PremiumCompany Announcements
Ascletis Pharma Schedules Board Meeting to Review 2026 Interim Results and Dividend
7d ago
1672
Ascletis Advances Once-Monthly Obesity Drug ASC37 With Strong Preclinical Results
PremiumCompany Announcements
Ascletis Advances Once-Monthly Obesity Drug ASC37 With Strong Preclinical Results
14d ago
1672
Ascletis Showcases Preclinical Obesity Drug with Superior Weight-Loss Data at EASD 2026
PremiumCompany Announcements
Ascletis Showcases Preclinical Obesity Drug with Superior Weight-Loss Data at EASD 2026
18d ago
1672
Ascletis Advances First-in-Class Oral GLP/GIP Combo for Obesity
PremiumCompany Announcements
Ascletis Advances First-in-Class Oral GLP/GIP Combo for Obesity
26d ago
1672
Ascletis files U.S. INDs for next‑generation monthly obesity injections
PremiumCompany AnnouncementsAscletis files U.S. INDs for next‑generation monthly obesity injections
1M ago
1672
Ascletis Pharma Launches HK$300 Million Share Buyback Under Mandate
Premium
Company Announcements
Ascletis Pharma Launches HK$300 Million Share Buyback Under Mandate
1M ago
1672
Ascletis Pharma Wins Shareholder Backing for All AGM Resolutions and Capital Mandates
Premium
Company Announcements
Ascletis Pharma Wins Shareholder Backing for All AGM Resolutions and Capital Mandates
1M ago
1672
Ascletis Wins FDA Green Light for Monthly Obesity Drug ASC35 Phase I Trial
PremiumCompany Announcements
Ascletis Wins FDA Green Light for Monthly Obesity Drug ASC35 Phase I Trial
2M ago
1672
Ascletis Showcases Differentiated Oral Obesity Drugs at ADA 2026
PremiumCompany Announcements
Ascletis Showcases Differentiated Oral Obesity Drugs at ADA 2026
2M ago
1672
Ascletis Pharma Sets 2026 AGM and Seeks Renewal of Share Issuance Mandate
PremiumCompany Announcements
Ascletis Pharma Sets 2026 AGM and Seeks Renewal of Share Issuance Mandate
2M ago
1672
Ascletis Pharma Seeks Shareholder Approval to Modernize Governance Rules
PremiumCompany Announcements
Ascletis Pharma Seeks Shareholder Approval to Modernize Governance Rules
2M ago
1672
Ascletis to Showcase Promising Obesity Drug Pipeline at ECO 2026
PremiumCompany AnnouncementsAscletis to Showcase Promising Obesity Drug Pipeline at ECO 2026
3M ago
1672
Ascletis to Unveil Obesity and Metabolic Drug Data at ADA 2026
Premium
Company Announcements
Ascletis to Unveil Obesity and Metabolic Drug Data at ADA 2026
3M ago
1672
Ascletis Completes U.S. Phase II Enrollment for Oral GLP-1 Diabetes Drug ASC30
Premium
Company Announcements
Ascletis Completes U.S. Phase II Enrollment for Oral GLP-1 Diabetes Drug ASC30
4M ago
1672
Ascletis Advances Fixed-Dose Oral Obesity Pill Toward U.S. FDA IND in 2026
PremiumCompany Announcements
Ascletis Advances Fixed-Dose Oral Obesity Pill Toward U.S. FDA IND in 2026
4M ago
1672
Ascletis Deepens R&D Push in Obesity Drugs as 2025 Loss Widens
PremiumCompany Announcements
Ascletis Deepens R&D Push in Obesity Drugs as 2025 Loss Widens
4M ago
1672
Ascletis Pharma Sets March 31 Board Meeting to Approve 2025 Results and Consider Dividend
PremiumCompany Announcements
Ascletis Pharma Sets March 31 Board Meeting to Approve 2025 Results and Consider Dividend
5M ago
1672
Ascletis Advances Oral Amylin Agonist ASC39 Toward U.S. IND for Obesity
PremiumCompany Announcements
Ascletis Advances Oral Amylin Agonist ASC39 Toward U.S. IND for Obesity
5M ago
1672
Ascletis Posts Positive U.S. Phase II Data for Monthly GLP-1 Obesity Drug ASC30
PremiumCompany AnnouncementsAscletis Posts Positive U.S. Phase II Data for Monthly GLP-1 Obesity Drug ASC30
5M ago
1672
Ascletis Advances Oral Amylin Obesity Drug ASC36 Toward U.S. Clinical Trials
Premium
Company Announcements
Ascletis Advances Oral Amylin Obesity Drug ASC36 Toward U.S. Clinical Trials
6M ago
1672
Ascletis Raises HK$835 Million to Fund Global Phase III Obesity Drug Trials
Premium
Company Announcements
Ascletis Raises HK$835 Million to Fund Global Phase III Obesity Drug Trials
6M ago
1672

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >